ArticleRMD open2026
Sjögren's disease metabolome reveals biomarker signatures to characterise patients and assess disease activity.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The systemic immune-inflammation biomarkers in Sjögren's disease: associations with disease activity and extraglandular manifestations in a multicentric Italian cohort.Internal and emergency medicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSjögren's disease (SjD) is a chronic systemic autoimmune disease with heterogeneous glandular and extraglandular manifestations. Although aetiology and pathogenesis of SjD remains elusive, emergence of autoreactive T and B lymphocytes is crucial in disease development. In this study, the metabolome of patients with SjD was characterised to improve disease understanding and to identify biomarkers as tools to aid drug development.
methodThe metabolome was investigated in saliva, tears and plasma samples from two independent cohorts from Poland (PL) and the UK using a mass spectrometry screening platform with 4500 reference metabolites. The PL cohort included 30 healthy subjects and 32 patients with SjD. The UK cohort encompassed longitudinal samples from 13 healthy subjects and 12 patients with SjD.
resultsPatient heterogeneity was reflected in the metabolome across all three matrices (plasma, saliva and tears) with consistent disturbances in the amino acid metabolism and transport pathway. A biomarker signature was developed using both cohorts, which allowed to characterise patients with milder and more severe disease activity. The relevance of the biomarker signature was supported by the presence of metabolites linked to pathways such as gamma-glutamyl cycle, pyrimidine metabolism and sex steroid hormones, which have previously been described to be deregulated in patients with SjD and other autoimmune diseases.
conclusionA plasma metabolome biomarker signature was developed that can be implemented in clinical studies by simple blood collection. The biomarker signature allows to characterise disease activity of patients with SjD at baseline and provides a basis for future studies to investigate its potential utility in monitoring therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.